Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- Viruses as pathogens and tools
- Viruses as vaccines
- Viruses as vaccines - results
- The frontier: from viruses to oncolytics
- Oncolytic virotherapy - definition
- The promise of oncolytic virotherapy
- Targeting viruses to tumors: layers of specificity
- DNA viruses in cancer clinical trials
- RNA viruses in cancer clinical trials
- Measles as an oncolytic virus
- Regression of lymphoma after measles infection
- Pre-clinical trials with oncolytic measles viruses
- Biology of measles virus
- Measles and non-segmented negative RNA viruses
- Measles virus particles
- Expression of reproter genes in measles virus
- Measles virus - genome and particle activation
- Matrix metalloproteinases (MMP)
- In situ activation of viruses by MMPs
- MV fusion protein activation and inactivation
- Conferring MMP-2 specific activation
- Recovery of MMP-activated MV
- MV-MMP-A: fusion of MMP-secreting cells
- MV-MMP-A1: safety and efficacy
- Summary - first layer of targeting
- Tropism retargeting - layer 2, cell entry
- The strategy: modification of attachment protein H
- Retargeting cell entry (1)
- Measles virus receptor SLAM/CD46 based tests
- Mutants supporting SLAM/CD46 dependent fusion
- SLAM/CD46-dependent fusion important residues
- Entry through targeted receptor
- Retargeting cell entry (2)
- Retargeting tropism: layer 3 and layer 4
- Retargeting tropism: spread (1)
- Oncolytic MV have a mutated Zn-binding domain
- Properties of the mutated V protein
- Conservative modification of V protein
- Retargeting tropism: spread (2)
- Interaction of V protein with mda5 and STAT2
- Interaction of V and P with STAT1
- Recombinant measles virus with desired mutations
- Retargeting tropism: spread (3)
- Topical clinical trials
- Oncolytic viruses as cancer therapeutics
- Head and neck carcinoma: approved regimen
- Ongoing trials: prostate cancer
- Ongoing trials: glioma
- Ongoing trials: advanced liver tumors
- Ongoing trials: superficial tumors
- Ovarian carcinoma, multiple myeloma
- Summary of clinical trials
- Improving efficacy of oncolytic virotherapy activity
- Choosing the ideal oncolytic virus
- Acknowledgements
Topics Covered
- Viruses: molecular biology and reverse genetics
- Tropism determinants: entry and post-entry levels
- Tropism targeting: protease activation, receptor attachment, transcription/replication, spread
- Cancer clinical trials: recombinant adeno-, herpes, vaccinia and measles viruses
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Cattaneo, R. (2007, October 1). From viruses to oncolytics [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 13, 2024, from https://doi.org/10.69645/PXFF1674.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Roberto Cattaneo has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.